Heron Therapeutics appoints Michael Kaseta to Board of Directors

HERON THERAPEUTICS, INC. /DE/

Michael Kaseta, CFO/COO of Liquidia, appointed to Heron's Board effective Nov. 4, 2024.
Kaseta brings biopharma finance and commercial expertise; served as CFO at Aerami and Aralez.
Previously CFO of Sanofi North America, managing a $10B business across 100+ products.
Will receive standard non-employee director compensation and enter indemnification agreement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Kaseta

Director

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2024-11-04
Filed: November 4, 2024, 6:59 PM ET

On November 4, 2024, the Board of Directors (the "Board") of Heron Therapeutics, Inc. (the "Company") appointed Michael Kaseta to the Board to serve for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Kaseta was appointed as Director at HERON THERAPEUTICS, INC. /DE/.

Action: appointed
Role: Director

Exact text from the filing

On November 4, 2024, the Board of Directors (the "Board") of Heron Therapeutics, Inc. (the "Company") appointed Michael Kaseta to the Board to serve for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.

View on SEC.gov

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-24-120902

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.